These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25114529)

  • 1. 2'-(2-bromohexadecanoyl)-paclitaxel conjugate nanoparticles for the treatment of non-small cell lung cancer in an orthotopic xenograft mouse model.
    Peng L; Schorzman AN; Ma P; Madden AJ; Zamboni WC; Benhabbour SR; Mumper RJ
    Int J Nanomedicine; 2014; 9():3601-10. PubMed ID: 25114529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a novel orthotopic non-small cell lung cancer model and therapeutic benefit of 2'-(2-bromohexadecanoyl)-docetaxel conjugate nanoparticles.
    Peng L; Feng L; Yuan H; Benhabbour SR; Mumper RJ
    Nanomedicine; 2014 Oct; 10(7):1497-506. PubMed ID: 24709328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oil-filled lipid nanoparticles containing 2'-(2-bromohexadecanoyl)-docetaxel for the treatment of breast cancer.
    Feng L; Benhabbour SR; Mumper RJ
    Adv Healthc Mater; 2013 Nov; 2(11):1451-7. PubMed ID: 23606545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
    He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
    Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer.
    Werner ME; Cummings ND; Sethi M; Wang EC; Sukumar R; Moore DT; Wang AZ
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):463-468. PubMed ID: 23708084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2'-Behenoyl-paclitaxel conjugate containing lipid nanoparticles for the treatment of metastatic breast cancer.
    Ma P; Rahima Benhabbour S; Feng L; Mumper RJ
    Cancer Lett; 2013 Jul; 334(2):253-62. PubMed ID: 22902506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
    Zou Y; Fu H; Ghosh S; Farquhar D; Klostergaard J
    Clin Cancer Res; 2004 Nov; 10(21):7382-91. PubMed ID: 15534115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of paclitaxel loaded pegylated gelatin targeted nanoparticles for improved treatment efficacy in non-small cell lung cancer (NSCLC): an in vitro and in vivo evaluation study.
    Gu M; Luan J; Song K; Qiu C; Zhang X; Zhang M
    Acta Biochim Pol; 2021 Aug; 68(4):583-591. PubMed ID: 34355554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel-loaded redox-sensitive nanoparticles based on hyaluronic acid-vitamin E succinate conjugates for improved lung cancer treatment.
    Song Y; Cai H; Yin T; Huo M; Ma P; Zhou J; Lai W
    Int J Nanomedicine; 2018; 13():1585-1600. PubMed ID: 29588586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel-loaded poly(glycolide-co-ε-caprolactone)-b-D-α-tocopheryl polyethylene glycol 2000 succinate nanoparticles for lung cancer therapy.
    Zhao T; Chen H; Dong Y; Zhang J; Huang H; Zhu J; Zhang W
    Int J Nanomedicine; 2013; 8():1947-57. PubMed ID: 23696703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved response to nab-paclitaxel compared with cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancer.
    Shao H; Tang H; Salavaggione OE; Yu C; Hylander B; Tan W; Repasky E; Adjei AA; Dy GK
    J Thorac Oncol; 2011 Jun; 6(6):998-1005. PubMed ID: 21532503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo.
    Ni L; Xu J; Zhao F; Dai X; Tao J; Pan J; Shi A; Shen Z; Su C; Zhang Y
    Eur J Pharmacol; 2021 May; 899():174054. PubMed ID: 33771522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Porous quaternized chitosan nanoparticles containing paclitaxel nanocrystals improved therapeutic efficacy in non-small-cell lung cancer after oral administration.
    Lv PP; Wei W; Yue H; Yang TY; Wang LY; Ma GH
    Biomacromolecules; 2011 Dec; 12(12):4230-9. PubMed ID: 22044456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of paclitaxel is significantly enhanced by a novel proapoptotic agent in non-small cell lung cancer.
    Razi SS; Rehmani S; Li X; Park K; Schwartz GS; Latif MJ; Bhora FY
    J Surg Res; 2015 Apr; 194(2):622-630. PubMed ID: 25498514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane.
    Feng Z; Zhao G; Yu L; Gough D; Howell SB
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):923-30. PubMed ID: 19685054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel efficacy is increased by parthenolide via nuclear factor-kappaB pathways in in vitro and in vivo human non-small cell lung cancer models.
    Gao ZW; Zhang DL; Guo CB
    Curr Cancer Drug Targets; 2010 Nov; 10(7):705-15. PubMed ID: 20578985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells.
    Yang T; Choi MK; Cui FD; Lee SJ; Chung SJ; Shim CK; Kim DD
    Pharm Res; 2007 Dec; 24(12):2402-11. PubMed ID: 17828616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor Progression of Non-Small Cell Lung Cancer Controlled by Albumin and Micellar Nanoparticles of Itraconazole, a Multitarget Angiogenesis Inhibitor.
    Zhang L; Liu Z; Yang K; Kong C; Liu C; Chen H; Huang J; Qian F
    Mol Pharm; 2017 Dec; 14(12):4705-4713. PubMed ID: 29068216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhalable nanostructured lipid particles of 9-bromo-noscapine, a tubulin-binding cytotoxic agent: in vitro and in vivo studies.
    Jyoti K; Kaur K; Pandey RS; Jain UK; Chandra R; Madan J
    J Colloid Interface Sci; 2015 May; 445():219-230. PubMed ID: 25622047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTD modified paclitaxel anti-resistant liposomes for treatment of drug-resistant non-small cell lung cancer.
    Ju RJ; Cheng L; Xiao Y; Wang X; Li CQ; Peng XM; Li XT
    J Liposome Res; 2018 Sep; 28(3):236-248. PubMed ID: 28480778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.